158 related articles for article (PubMed ID: 20508967)
1. Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil.
Brustoloni YM; Cunha RV; Cônsolo LZ; Oliveira AL; Dorval ME; Oshiro ET
Infection; 2010 Aug; 38(4):261-7. PubMed ID: 20508967
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
4. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
5. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
6. [Visceral leishmaniasis: retrospective study on factors associated with lethality].
Alvarenga DG; Escalda PM; Costa AS; Monreal MT
Rev Soc Bras Med Trop; 2010; 43(2):194-7. PubMed ID: 20464152
[TBL] [Abstract][Full Text] [Related]
7. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
8. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
Shahian M; Alborzi A
Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
[TBL] [Abstract][Full Text] [Related]
9. [Emergent outbreak of visceral leishmaniasis in Mato Grosso do Sul State].
Oliveira AL; Paniago AM; Dorval ME; Oshiro ET; Leal CR; Sanches M; Cunha RV; Bóia MN
Rev Soc Bras Med Trop; 2006; 39(5):446-50. PubMed ID: 17160321
[TBL] [Abstract][Full Text] [Related]
10. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
11. Pediatric visceral leishmaniasis in southern France.
Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
[TBL] [Abstract][Full Text] [Related]
12. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
14. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
Gradoni L; Gramiccia M; Scalone A
Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
[TBL] [Abstract][Full Text] [Related]
15. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil.
Alexandrino-de-Oliveira P; Santos-Oliveira JR; Dorval ME; Da-Costa Fd; Pereira GR; da Cunha RV; Paniago AM; Da-Cruz AM
Mem Inst Oswaldo Cruz; 2010 Aug; 105(5):692-7. PubMed ID: 20835619
[TBL] [Abstract][Full Text] [Related]
16. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
17. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
18. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Segura I; García-Bolao I
Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
20. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]